Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous CAR-CD28-expressing T lymphocytes

A preparation of autologous T lymphocytes expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) C-type-lectin-like molecule-1 (CLL1; C-type lectin domain family 12 member A; CLEC12A) linked to the CD28 co-stimulatory signaling domain, with potential immunomodulating and antineoplastic activities. Upon administration, the autologous CLL1-CAR-CD28-expressing T lymphocytes specifically target and bind to CLL1-expressing tumor cells. This induces selective toxicity in tumor cells that express the CLL1 antigen. CLL1, a member of the C-type lectin/C-type lectin-like domain (CTL/CTLD) superfamily, is overexpressed in leukemic stem cells (LSCs) and plays an important role in disease progression and relapse for myeloid malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:autologous anti-CLL-1 CAR T cells
autologous CLL-1.CAR T cells
autologous CLL1-specific CAR T lymphocytes
autologous CLL1-targeted CAR T cells
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search